drugset
drugset / Trial / NCT04034134

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

NCT04034134 ↗

Phase 2 Completed 111 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.

Timeline

Start
2019-11-18
Primary completion
2021-11-26
Completion
2021-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 50 mg Oral
Subject Jaktinib Unknown 150 mg Oral
Subject Jaktinib Unknown 200 mg Oral

Indications

alopecia areata